ArticleMedical oncology (Northwood, London, England)2016
Micro-RNA (miRNA) profile in Hodgkin lymphoma: association between clinical and pathological variables.
Article in Medical oncology (Northwood, London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 67 citations in OpenAlex.
- miR-512-3p as a Potential Biomarker of Poor Outcome in Pediatric Medulloblastoma.Cerebellum (London, England) · 2025Article
- MicroRNAs implicated in canine diffuse large B-cell lymphoma prognosis.FEBS open bio · 2024Article
- Diagnostic and prognostic role of microRNA-525 in different cancers: a systematic review and meta-analysis.Translational cancer research · 2024Article
- LncRNA PCGEM1 facilitates cervical cancer progression via miR-642a-5p/KIF5B axis.Oncology research · 2024Article
- MiR-525-5p inhibits diffuse large B cell lymphoma progression via the Myd88/NF-κB signaling pathway.PeerJ · 2023Article
- Identification of the critical genes and miRNAs in hepatocellular carcinoma by integrated bioinformatics analysis.Medical oncology (Northwood, London, England) · 2022Article
- Protein tyrosine phosphatase non-receptor type 12 (PTPN12), negatively regulated by miR-106a-5p, suppresses the progression of hepatocellular carcinoma.Human cell · 2022Article
- The biomarkers of key miRNAs and gene targets associated with extranodal NK/T-cell lymphoma.Open medicine (Warsaw, Poland) · 2022Article
- Circular RNA_0074027 participates in cell proliferation, apoptosis and metastasis of colorectal cancer cells through regulation of miR‑525‑3p.Molecular medicine reports · 2021Article
- MicroRNA signature in classical Hodgkin lymphoma.Journal of applied genetics · 2021Review
- MicroRNA‑642a‑5p inhibits colon cancer cell migration and invasion by targeting collagen type I α1.Oncology reports · 2021Article
- Identification of miR-320 family members as potential diagnostic and prognostic biomarkers in myelodysplastic syndromes.Scientific reports · 2021Article
- Review
- Peripheral Blood Cells from Patients with Hodgkin's and Diffuse Large B Cell Lymphomas May Be a Better Source of Candidate Diagnostic miRNAs Than Circulating miRNAs.BioMed research international · 2021Article
- PMDFI: Predicting miRNA-Disease Associations Based on High-Order Feature Interaction.Frontiers in genetics · 2021Article
- circEYA1 Functions as a Sponge of miR-582-3p to Suppress Cervical Adenocarcinoma Tumorigenesis via Upregulating CXCL14.Molecular therapy. Nucleic acids · 2020Article
- Serum miR-339-3p as a potential diagnostic marker for non-small cell lung cancer.Cancer biology & medicine · 2020Article
- Ectopic Expression of miR-532-3p Suppresses Bone Metastasis of Prostate Cancer Cells via Inactivating NF-κB Signaling.Molecular therapy oncolytics · 2020Article
- Expression and significance of miR-654-5p and miR-376b-3p in patients with colon cancer.World journal of gastrointestinal oncology · 2020Article
- Risk, Diagnostic and Predictor Factors for Classical Hodgkin Lymphoma in HIV-1-Infected Individuals: Role of Plasma Exosome-Derived miR-20a and miR-21.Journal of clinical medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
miRNAs are small RNAs and control the expression of protein-encoding genes. The aim of this study was to determine the association between miRNA profile and clinical variables including age, stage, B symptom, histopathologic subtype, response to treatment, disease-free survival (DFS) and overall survival (OS) in classical Hodgkin lymphoma (cHL). A total of 377 miRNAs were studied by qPCR in 32 cases with cHL, and results were compared with 60 samples taken from cases with reactive lymphadenopathy. Biogazelle qbasePLUS 2.0 software was used to analyze the results. miR-582-3p, miR-525-3p, miR-448, miR-512-3p, miR-642a-5p, miR-876-5p, miR-532-3p, miR-654-5p, miR-128, miR-145-5p, miR-15b-5p, miR-328 and miR-660-5p were found to be decreased in cHL compared with controls. In contrast, miR-34a-5p (2.626-fold), miR-146a-5p (4.32-fold), miR-93-5p (2.347-fold), miR-20a-5p (4.930-fold), miR-339-3p (4.948-fold), miR-324-3p (4.98-fold), miR-372 (7.038-fold), miR-127-3p (8.234-fold), miR-155-5p (4.947-fold), miR-320a (17.502-fold) and miR-370 (21.479-fold) (p < 0.05) were found to be increased in cHL. There was no difference in miRNA profile according to the age, sex, stage, response to treatment, DFS and OS. However, miR-889 was found to be increased in patients with B symptom and miR-127-3p was found to be increased in nodular sclerosing subtype. Some miRNAs increase and some decrease in cHL. However, there was no clinical association between clinical variables and with the majority of the miRNA profile studied in this study. miR-889 and miR-127-3p were related to B symptom and nodular sclerosis subtype, respectively. We need more studies evaluating miRNA profile and clinical outcome in Hodgkin Lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.